Pharma Division

The Pharmaceutical Division is one of Ariti’s fastest growing sectors

Ariti has been active in the pharmaceutical area since the end of 2008.

The first pharmaceutical product (LETRAFEM/ letrozole), was authorised back in June 2011 and quickly gained recognition in Oncology for the treatment of breast cancer.

In 2019, a new business unit was created, consisting of executives specialized in orphan drugs, aiming to offer therapeutic solutions to patients in Greece and Cyprus, diagnosed with a rare disease.

The scientifically trained personnel of the pharmaceutical division interacts with healthcare professionals and participates continuously in the most important domestic or international medical events. Α well-organized Regulatory Affairs and Pharmacovigilance department constitutes another crucial part of this division, with personnel of great expertise.

Finally, with the constant research of the global market and the longstanding cooperation with reliable companies of the pharmaceutical industry, Ariti deploys an ambitious development plan for the years to come.


Letrafem®LetrozoleAntineoplastic Agent,Non Steroid Aromatase inhibitorΦΟΧ
Rectoxal®OxaliplatinAntineoplastic Agent, Platinum CompoundΦΟΧ
Irican®Irinotecan hydrochloride trihydrateChemotherapeutic agent 
Topoisomerase inhibitor
Topocan®Topotecan hydrochlorideChemotherapeutic agent 
Topoisomerase inhibitor
Gemlag®Gemcitabine HydrochlorideChemotherapeutic agent, nucleoside analogΦΟΧ
Capibine®CapecitabineAntineoplastic agent – Pyrimidine analogueΦΟΧ
Sunitinib AritiSunitinib MalateAntineoplastic and immunomodulatory agents. Antineoplastic drugs.ΦΟΧ
Ariti 500mg
AbirateroneHormone (endocrine) therapy, Other hormone antagonists and related agentsΦΟΧ
Alfuzin®Alfuzosin HydrochlorideMedications used in disorders of the urinary system. Drugs used in benign prostatic hypertrophyΦΟΧ
Lutrak®BicalutamideAntineoplastic agent – AntiandrogenΦΟΧ
Solicin®Solifenacin succinateGastrointestinal antispasmodicsΦΟΧ
Tamsulosin AritiTamsulosin HydrochlorideDrugs used in benign prostatic hypertrophy, Alpha-adrenoreceptor antagonistΦΟΧ
Tadalafil AritiTadalafilDrugs used in the treatment of erectile dysfunction, Phosphodiesterase type 5 inhibitorΦΟΧ
Solifenacin + Tamsulosin AritiSolifenacin Succinate + Tamsulosin HydrochlorideMedicines for diseases of the urinary system. Drugs used in benign prostatic hypertrophy.ΦΟΧ
Quetiapine AritiQuetiapine FumarateDrugs for Central Nervous System. Antipsychotic drugs. Diazepines, oxazepines and thiazepines.ΦΟΧ
Peziled®Donepezil HydrochlorideTreatment of Alzheimer’s disease, Acetylcholinesterase inhibitorΦΟΧ
Escitalopram AritiEscitalopram OxalateAntidepressants, Selective serotonin reuptake inhibitorΦΟΧ
Memantine AritiMemantine HydrochlorideAnti-dementia drugs, NMDA receptor antagonistΦΟΧ
Rasagiline AritiRasagiline tartrateΤreatment of Parkinson’s disease, Selective monoamine oxidase inhibitorΦΟΧ
Reoxyl®Iron Sucrose(Iron ΙΙΙ)Antianemic Preparations,Saccharated Iron OxideΦΟΧ
Aricitol®ParicalcitolAnti-parathyroid agents, Synthetic vitamin D analogΦΟΧ
Magnesium Sulfate AritiMagnesium Sulfate HeptahydrateDigestive tract and metabolism. Additions of metal elements.ΦΟΧ
Adrenaline AritiEpinephrineAdrenergic agents for hospital useΦΟΧ
Atropine AritiAtropine SulfateAlkaloids of euthalia, tertiary amines, muscarinic antagonist
CALCIUM GLUCONATE/ARITICalcium GluconateDigestive tract and metabolism. Mineral supplementsΦΟΧ
Colistimethate Sodium AritiColistimethate SodiumAnti-infective drugs for systemic administration. Antibiotics for systemic administration.ΦΟΧ
Dexmedetomidine Ariti Dexmedetomidine HydrochloridePsychotropic and Sedatives.ΦΟΧ
Sugammadex AritiSugammadex SodiumOther medicinesΦΟΧ
Lenalidomide  AritiLenalidomideOther immunosuppressantsΦΟΧ
Fenedim®GelDimetindene maleateAntihistamines for topical use, Drugs of the alkylamine groupΦΟΧ

On Rare Disease Day 2019, 28th of February, Ariti launched a new business unit within the pharmaceutical division, working exclusively on rare disorders. The newly formed team is composed of experienced personnel in the field of orphan medicinal products both in local and international markets. Our main goal would be to offer therapeutic solutions to patients suffering from rare diseases in Greece and Cyprus, through collaborations with other pharmaceutical companies.

  • Access to therapy
    We engage in different steps during the lifecycle of a product, guiding our partners on early access programs (EAPs), named patient programs (NPPs) and Pricing & Reimbursement process.
  • Product handling
    We ensure proper storage and transport conditions for the pharmaceutical products through the country
  • Pharmacovigilance
    The Pharmacovigilance department provides comprehensive support in managing the safety profile of pharmaceutical products by applying special procedures based on the current legislation.
  • Marketing and Sales
    Our goal is to achieve ideal market penetration for a specific pharmaceutical product. Our priority is to apply strategies to increase disease awareness, engage HCPs into active patient identification initiatives and expose stakeholders to the added value of a given pharmaceutical product.  
  • Market and Disease Analysis
    We provide analysis on disease prevalence, centers of excellence, diagnostic centers, patient organizations as well as HCPs and KOL networks dealing with a specific disorder. Our report provides information on current disease management guidelines as well as competitive landscape analysis.


For scientific information and pharmacovigilance please call +30 2108002650 οr +30 6981672031, or send us an e-mail at: